Effects of Probiotics on Chemotherapy-induced Diarrhea

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763.
   PubMed Web of Science ®Google Scholar
• Kornblau S, Benson AB, Catalano R, Champlin RE, Engelking C, Field M, Ippoliti C, Lazarus HM, Mitchell E, Rubin J, et al. Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. J Pain Symptom Manage. 2000;19(2):118–129. doi: 10.1016/s0885-3924(99)00149-9.
   PubMed Web of Science ®Google Scholar
• Koselke E, Kraft S. Chemotherapy-induced diarrhea: options for treatment and prevention. J Hematol Oncol Pharm. 2012;2(4):143–151.
   Google Scholar
• Richardson G, Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract. 2007;13(4):181–198. doi: 10.1177/1078155207077335.
   PubMedGoogle Scholar
• Morelli L, Capurso L. FAO/WHO guidelines on probiotics: 10 years later. J Clin Gastroenterol. 2012;46:S1–S2. doi: 10.1097/MCG.0b013e318269fdd5.
   PubMed Web of Science ®Google Scholar
• Fijan S. Microorganisms with claimed probiotic properties: an overview of recent literature. Int J Environ Res Public Health. 2014;11(5):4745–4767. doi: 10.3390/ijerph110504745.
   PubMed Web of Science ®Google Scholar
• Williams NT. Probiotics. Am J Health Syst Pharm. 2010;67(6):449–458. doi: 10.2146/ajhp090168.
   PubMed Web of Science ®Google Scholar
• Liao W, Chen C, Wen T, Zhao Q. Probiotics for the prevention of antibiotic-associated diarrhea in adults: a meta-analysis of randomized placebo-controlled trials. J Clin Gastroenterol. 2021;55(6):469–480. doi: 10.1097/mcg.0000000000001464.
   PubMed Web of Science ®Google Scholar
• de Moreno de LeBlanc A, Matar C, Perdigón G. The application of probiotics in cancer. Br J Nutr. 2007;98(Suppl 1):S105–S110. doi: 10.1017/s0007114507839602.
   PubMedGoogle Scholar
• Kong C, Gao R, Yan X, Huang L, Qin H. Probiotics improve gut microbiota dysbiosis in obese mice fed a high-fat or high-sucrose diet. Nutrition. 2019;60:175–184. doi: 10.1016/j.nut.2018.10.002.
   PubMed Web of Science ®Google Scholar
• Harper A, Naghibi MM, Garcha D. The role of bacteria, probiotics and diet in irritable bowel syndrome. Foods. 2018;7(2):13. doi: 10.3390/foods7020013.
   PubMed Web of Science ®Google Scholar
• Zaharuddin L, Mokhtar NM, Muhammad Nawawi KN, Raja Ali RA. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer. BMC Gastroenterol. 2019;19(1):131. doi: 10.1186/s12876-019-1047-4.
   PubMed Web of Science ®Google Scholar
• Chen J, Liang H, Lu J, He Y, Lai R. Probiotics improve postoperative adaptive immunity in colorectal cancer patients: a systematic review and meta-analysis. Nutr Cancer. 2022;74(8):2975–2982. doi: 10.1080/01635581.2022.2056619.
   PubMed Web of Science ®Google Scholar
• Lu D, Yan J, Liu F, Ding P, Chen B, Lu Y, Sun Z. Probiotics in preventing and treating chemotherapy-induced diarrhea: a meta-analysis. Asia Pac J Clin Nutr. 2019;28(4):701–710. doi: 10.6133/apjcn.201912_28(4).0005.
   PubMed Web of Science ®Google Scholar
• Chua LL, Rajasuriar R, Azanan MS, Abdullah NK, Tang MS, Lee SC, Woo YL, Lim YAL, Ariffin H. Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation. Microbiome. 2017;5(1):1–14. 10.1186/s40168-017-0250-1
   PubMedGoogle Scholar
• Yang L, Pei Z. Bacteria, inflammation, and colon cancer. World J Gastroenterol. 2006;12(42):6741. 10.3748/wjg.v12.i42.6741
   PubMed Web of Science ®Google Scholar
• Yu AQ, Li L. The potential role of probiotics in cancer prevention and treatment. Nutr Cancer. 2016;68(4):535–544. doi: 10.1080/01635581.2016.1158300.
   PubMed Web of Science ®Google Scholar
• Benson ABR, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JAJr, McCallum R, Mitchell EP, O’Dorisio TM, Vokes EE, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22(14):2918–2926. doi: 10.1200/jco.2004.04.132.
   PubMed Web of Science ®Google Scholar
• Bauer T, Cho BC, Heist R, Bazhenova L, Werner T, Goel S, Kim DW, Adkins D, Carvajal RD, Alva A, et al. First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. Invest New Drugs. 2022;40(5):990–1000. doi: 10.1007/s10637-022-01274-y.
   PubMed Web of Science ®Google Scholar
• Feng Z, Curti BD, Quinn DI, Strother JM, Chen Z, Agnor R, Beer TM, Ryan CW. A phase II, single-arm trial of sunitinib and erlotinib in advanced renal cell carcinoma. Clin Genitourin Cancer. 2022;20(5):415–422. doi: 10.1016/j.clgc.2022.04.018.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Diarrhea; 2020 [accessed 2023 Jan 30]. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/stool-or-urine-changes/diarrhea.html.
   Google Scholar
• Lee CK, Chon HJ, Kwon WS, Ban HJ, Kim SC, Kim H, Jeung HC, Chung J, Rha SY. The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients. Genomics Inform. 2022;20(3):e29. doi: 10.5808/gi.22051.
   PubMedGoogle Scholar
• Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer. 2008;112(9):1932–1940. doi: 10.1002/cncr.23370.
   PubMed Web of Science ®Google Scholar
• van Rees JM, Hartman W, Nuyttens J, Oomen-de Hoop E, van Vugt JLA, Rothbarth J, Verhoef C, van Meerten E. Relation between body composition and severe diarrhea in patients treated with preoperative chemoradiation with capecitabine for rectal cancer: a single-centre cohort study. BMC Gastroenterol. 2021;21(1):313. doi: 10.1186/s12876-021-01886-3.
   PubMed Web of Science ®Google Scholar
• Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51–63. doi: 10.1177/1758834009355164.
   PubMedGoogle Scholar
• Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Burns J, Keefe DM. Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med. 2007;232(1):96–106.
   PubMed Web of Science ®Google Scholar
• Yu HY, Lee CY, Lin LG, Chao Y, Li CP. Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: a real-world experience. J Chin Med Assoc. 2022;85(1):42–50. doi: 10.1097/jcma.0000000000000650.
   PubMed Web of Science ®Google Scholar
• Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, Ishii H, Mizusawa J, Katayama H, Kataoka T, et al. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Eur J Cancer. 2023;181:135–144. doi: 10.1016/j.ejca.2022.12.014.
   PubMed Web of Science ®Google Scholar
• Ohba A, Ueno H, Shiba S, Okano N, Kobayashi T, Nagashima F, Sasahira N, Sasaki M, Imaoka H, Sakamoto Y, et al. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: a multicenter phase 1b dose-escalation and dose-expansion clinical trial. Eur J Cancer. 2022;174:40–47. doi: 10.1016/j.ejca.2022.06.010.
   PubMed Web of Science ®Google Scholar
• Edelman MJ, Dvorkin M, Laktionov K, Navarro A, Juan-Vidal O, Kozlov V, Golden G, Jordan O, Deng CQ, Bentsion D, et al. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer. Lung Cancer. 2022;166:135–142. doi: 10.1016/j.lungcan.2022.03.003.
   PubMed Web of Science ®Google Scholar
• Antoniotti C, Germani MM, Rossini D, Lonardi S, Pietrantonio F, Santini D, Marmorino F, Allegrini G, Daniel F, Raimondi A, et al. FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies. Eur J Cancer. 2022;167:23–31. doi: 10.1016/j.ejca.2022.02.031.
   PubMed Web of Science ®Google Scholar
• Visacri MB, Duarte NC, Lima TM, de Souza RN, Cobaxo TS, Teixeira JC, Barbosa CR, Dias LP, Tavares MG, Pincinato EC, et al. Adverse reactions and adherence to capecitabine: a prospective study in patients with gastrointestinal cancer. J Oncol Pharm Pract. 2022;28(2):326–336. doi: 10.1177/1078155221989420.
   PubMed Web of Science ®Google Scholar
• Javle MM, Oh DY, Ikeda M, Yong WP, Hsu K, Lindmark B, McIntyre N, Firth C. Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp). ESMO Open. 2022;7(1):100314. doi: 10.1016/j.esmoop.2021.100314.
   PubMed Web of Science ®Google Scholar
• Furuse J, Ueno M, Ikeda M, Okusaka T, Teng Z, Furuya M, Ioka T. Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial. Jpn J Clin Oncol. 2023;53(2):130–137. doi: 10.1093/jjco/hyac177.
   PubMed Web of Science ®Google Scholar
• Hu Z, Sun S, Zhao X, Yu H, Wu X, Wang J, Chang J, Wang H. Rh-endostatin plus irinotecan/cisplatin as second-line therapy for advanced esophageal squamous cell carcinoma: an open-label, phase II study. Oncologist. 2022;27(4):e253–e312. doi: 10.1093/oncolo/oyab078.
   PubMed Web of Science ®Google Scholar
• Ueno M, Nakamori S, Sugimori K, Kanai M, Ikeda M, Ozaka M, Furukawa M, Okusaka T, Kawabe K, Furuse J, et al. nal-IRI + 5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: randomized phase 2 trial in Japanese patients. Cancer Med. 2020;9(24):9396–9408. doi: 10.1002/cam4.3558.
   PubMed Web of Science ®Google Scholar
• Krishnamurthi SS, Macraon C. Management of acute chemotherapy-related diarrhea. Up-to-date. [accessed 2019 Aug5].
   Google Scholar
• Cherny NI. Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. J Pain Symptom Manage. 2008;36(4):413–423. doi: 10.1016/j.jpainsymman.2007.10.007.
   PubMed Web of Science ®Google Scholar
• Logan RM, Gibson RJ, Bowen JM, Stringer AM, Sonis ST, Keefe DMK. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol. 2008;62(1):33–41. doi: 10.1007/s00280-007-0570-0.
   PubMed Web of Science ®Google Scholar
• Stringer AM, Gibson RJ, Bowen JM, Logan RM, Ashton K, Yeoh AS, Al-Dasooqi N, Keefe DM. Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol. 2009;90(5):489–499. doi: 10.1111/j.1365-2613.2009.00671.x.
   PubMed Web of Science ®Google Scholar
• Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Keefe DM. Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther. 2008;7(12):1919–1925. doi: 10.4161/cbt.7.12.6940.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 5.0. 2017; [accessed 2023 Jan 11]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.
   Google Scholar
• Visich KL, Yeo TP. The prophylactic use of probiotics in the prevention of radiation therapy-induced diarrhea. Clin J Oncol Nurs. 2010;14(4):467–473. doi: 10.1188/10.CJON.467-473.
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920–924. doi: 10.3109/00365529709011203.
   PubMed Web of Science ®Google Scholar
• Fioramonti J, Theodorou V, Bueno L. Probiotics: what are they? What are their effects on gut physiology? Best Pract Res Clin Gastroenterol. 2003;17(5):711–724. doi: 10.1016/S1521-6918(03)00075-1.
   PubMed Web of Science ®Google Scholar
• Yang B, Yue Y, Chen Y, Ding M, Li B, Wang L, Wang Q, Stanton C, Ross RP, Zhao J, et al. Lactobacillus plantarum CCFM1143 alleviates chronic diarrhea via inflammation regulation and gut microbiota modulation: a double-blind, randomized, placebo-controlled study. Front Immunol. 2021;12:746585. doi: 10.3389/fimmu.2021.746585.
   PubMed Web of Science ®Google Scholar
• Liu Z, Qin H, Yang Z, Xia Y, Liu W, Yang J, Jiang Y, Zhang H, Yang Z, Wang Y, et al. Randomised clinical trial: the effects of perioperative probiotic treatment on barrier function and post-operative infectious complications in colorectal cancer surgery - a double-blind study. Aliment Pharmacol Ther. 2011;33(1):50–63. doi: 10.1111/j.1365-2036.2010.04492.x.
   PubMed Web of Science ®Google Scholar
• Wilkins T, Sequoia J. Probiotics for gastrointestinal conditions: a summary of the evidence. Am Fam Physician. 2017;96(3):170–178.
   PubMed Web of Science ®Google Scholar
• Yeung C-Y, Chan W-T, Jiang C-B, Cheng M-L, Liu C-Y, Chang S-W, Chiang Chiau J-S, Lee H-C. Amelioration of chemotherapy-induced intestinal mucositis by orally administered probiotics in a mouse model. PLoS One. 2015;10(9):e0138746. 10.1371/journal.pone.0138746
   PubMed Web of Science ®Google Scholar
• Gigola G, Carriere P, Novoa Díaz MB, Perdigon G, Zwenger AO, Gentili C. Survival effect of probiotics in a rat model of colorectal cancer treated with capecitabine. World J Gastrointest Oncol. 2021;13(10):1518–1531. doi: 10.4251/wjgo.v13.i10.1518.
   PubMed Web of Science ®Google Scholar
• Sezer A, Usta U, Cicin I. The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea. Med Oncol. 2009;26(3):350–357. doi: 10.1007/s12032-008-9128-1.
   PubMed Web of Science ®Google Scholar
• Wu J, Wang J, Lin Z, Liu C, Zhang Y, Zhang S, Zhou M, Zhao J, Liu H, Ma X. Clostridium butyricum alleviates weaned stress of piglets by improving intestinal immune function and gut microbiota. Food Chem. 2023;405:135014. doi: 10.1016/j.foodchem.2022.135014.
   PubMed Web of Science ®Google Scholar
• Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, Bowen J, Gibson R, Saunders DP, Zadik Y, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126(19):4423–4431. doi: 10.1002/cncr.33100.
   PubMed Web of Science ®Google Scholar
• El-Atti SA, Wasicek K, Mark S, Hegazi R. Use of probiotics in the management of chemotherapy-induced diarrhea: a case study. J Parenter Enteral Nutr. 2009;33(5):569–570. doi: 10.1177/0148607109332004.
   PubMed Web of Science ®Google Scholar
• Mego M, Chovanec J, Vochyanova-Andrezalova I, Konkolovsky P, Mikulova M, Reckova M, Miskovska V, Bystricky B, Beniak J, Medvecova L, et al. Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complement Ther Med. 2015;23(3):356–362. doi: 10.1016/j.ctim.2015.03.008.
   PubMed Web of Science ®Google Scholar
• Österlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P, Kouri M, Elomaa I, Joensuu H. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 2007;97(8):1028–1034. doi: 10.1038/sj.bjc.6603990.
   PubMed Web of Science ®Google Scholar
• Tian Y, Li M, Song W, Jiang R, Li YQ. Effects of probiotics on chemotherapy in patients with lung cancer. Oncol Lett. 2019;17(3):2836–2848. doi: 10.3892/ol.2019.9906.
   PubMed Web of Science ®Google Scholar
• Chapman TM, Plosker GL, Figgitt DP. VSL#3 probiotic mixture. Drugs. 2006;66(10):1371–1387. doi: 10.2165/00003495-200666100-00006.
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Keefe DM, Sonis S, Jatoi A, Gernhardt D, Wang T, Doherty JP, Giri N, Nadanaciva S, O’Connell J, et al. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Ann Oncol. 2016;27(9):1712–1718. doi: 10.1093/annonc/mdw227.
   PubMed Web of Science ®Google Scholar
• Kaźmierczak-Siedlecka K, Folwarski M, Ruszkowski J, Skonieczna-Żydecka K, Szafrański W, Makarewicz W. Effects of 4 weeks of Lactobacillus plantarum 299v supplementation on nutritional status, enteral nutrition tolerance, and quality of life in cancer patients receiving home enteral nutrition - a double-blind, randomized, and placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2020;24(18):9684–9694. doi: 10.26355/eurrev_202009_23059.
   PubMed Web of Science ®Google Scholar
• Feng J, Gao M, Zhao C, Yang J, Gao H, Lu X, Ju R, Zhang X, Zhang Y. Oral administration of probiotics reduces chemotherapy-induced diarrhea and oral mucositis: a systematic review and meta-analysis. Front Nutr. 2022;9:823288. doi: 10.3389/fnut.2022.823288.
   PubMed Web of Science ®Google Scholar
• Golkhalkhali B, Rajandram R, Paliany AS, Ho GF, Wan Ishak WZ, Johari CS, Chin KF. Strain-specific probiotic (microbial cell preparation) and omega-3 fatty acid in modulating quality of life and inflammatory markers in colorectal cancer patients: a randomized controlled trial. Asia Pac J Clin Oncol. 2018;14(3):179–191. doi: 10.1111/ajco.12758.
   PubMed Web of Science ®Google Scholar
• Mohebian F, Mohammadzadeh Zarankesh S, Jenabian A, Ranjbar H . The effectiveness of yogurt + probiotic on chemotherapy-related diarrhea in patients with colorectal cancer: a randomized clinical trial. Middle East Journal of Cancer. 2023;14(1):127–135. doi: 10.30476/mejc.2021.91324.1620.
   Web of Science ®Google Scholar
• Wada M, Nagata S, Saito M, Shimizu T, Yamashiro Y, Matsuki T, Asahara T, Nomoto K. Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies. Support Care Cancer. 2010;18(6):751–759. doi: 10.1007/s00520-009-0711-6.
   PubMed Web of Science ®Google Scholar
• Whelan K, Myers CE. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. Am J Clin Nutr. 2010;91(3):687–703. doi: 10.3945/ajcn.2009.28759.
   PubMed Web of Science ®Google Scholar
• Redman MG, Ward EJ, Phillips RS. The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol. 2014;25(10):1919–1929. doi: 10.1093/annonc/mdu106.
   PubMed Web of Science ®Google Scholar
• Poncelet A, Ruelle L, Konopnicki D, Miendje Deyi VY, Dauby N. Saccharomyces cerevisiae fungemia: risk factors, outcome and links with S. boulardii-containing probiotic administration. Infect Dis Now. 2021;51(3):293–295. doi: 10.1016/j.idnow.2020.12.003.
   PubMedGoogle Scholar
• Suez J, Zmora N, Zilberman-Schapira G, Mor U, Dori-Bachash M, Bashiardes S, Zur M, Regev-Lehavi D, Ben-Zeev Brik R, Federici S, et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. 2018;174(6):1406.e16–1423.e16. doi: 10.1016/j.cell.2018.08.047.
   PubMed Web of Science ®Google Scholar
• Fei Z, Lijuan Y, Xi Y, Wei W, Jing Z, Miao D, Shuwen H. Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer. Gut Pathog. 2019;11:18. doi: 10.1186/s13099-019-0299-4.
   PubMed Web of Science ®Google Scholar
• Atasilp C, Biswas M, Jinda P, Nuntharadthanaphong N, Rachanakul J, Hongkaew Y, Vanwong N, Saokaew S, Sukasem C. Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C > T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: meta-analysis. Clin Transl Sci. 2022;15(7):1613–1633. doi: 10.1111/cts.13277.
   PubMed Web of Science ®Google Scholar
• Lee J-Y, Chu S-H, Jeon JY, Lee M-K, Park J-H, Lee D-C, Lee J-W, Kim N-K. Effects of 12 weeks of probiotic supplementation on quality of life in colorectal cancer survivors: a double-blind, randomized, placebo-controlled trial. Dig Liver Dis. 2014;46(12):1126–1132. doi: 10.1016/j.dld.2014.09.004.
   PubMedGoogle Scholar
• Liang D, Longgui N, Guoqiang X. Efficacy of different probiotic protocols in irritable bowel syndrome: a network meta-analysis. Medicine. 2019;98(27):e16068. doi: 10.1097/md.0000000000016068.
   PubMed Web of Science ®Google Scholar
• Jung S, Kim K-M, Youn S-M, Kim K-N. A randomized, double-Blind, placebo-controlled trial to evaluate the effects of multi-strain synbiotic in patients with functional diarrhea and high fecal calprotectin levels: a pilot study. Nutrients. 2022;14(23):5017. 10.3390/nu14235017
   PubMed Web of Science ®Google Scholar